| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 1368* | 2021 |
| Safety and efficacy of NVX-CoV2373 Covid-19 vaccine PT Heath, EP Galiza, DN Baxter, M Boffito, D Browne, F Burns, ... New England Journal of Medicine 385 (13), 1172-1183, 2021 | 943 | 2021 |
| Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) WG Dixon, KL Hyrich, KD Watson, M Lunt, J Galloway, A Ustianowski, ... Annals of the rheumatic diseases 69 (3), 522-528, 2010 | 899 | 2010 |
| Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results … JB Galloway, KL Hyrich, LK Mercer, WG Dixon, B Fu, AP Ustianowski, ... Rheumatology 50 (1), 124-131, 2011 | 779 | 2011 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial H Abo-Leyah, J Chalmers, H Loftus, M Spears Lancet, 2021 | 514* | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 441* | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 378 | 2021 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial E Abaleke, M Abbas, S Abbasi, A Abbott, A Abdelaziz, S Abdelbadiee, ... The Lancet 397 (10274), 605-612, 2021 | 317 | 2021 |
| A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis K Bechman, S Subesinghe, S Norton, F Atzeni, M Galli, AP Cope, ... Rheumatology 58 (10), 1755-1766, 2019 | 248 | 2019 |
| A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study JB Galloway, S Norton, RD Barker, A Brookes, I Carey, BD Clarke, R Jina, ... Journal of Infection 81 (2), 282-288, 2020 | 230 | 2020 |
| Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register JB Galloway, KL Hyrich, LK Mercer, WG Dixon, AP Ustianowski, M Helbert, ... Annals of the rheumatic diseases 70 (10), 1810-1814, 2011 | 229 | 2011 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 215 | 2022 |
| Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology … JB Galloway, LK Mercer, A Moseley, WG Dixon, AP Ustianowski, ... Annals of the rheumatic diseases 72 (2), 229-234, 2013 | 194 | 2013 |
| Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia RF D'Cruz, MD Waller, F Perrin, J Periselneris, S Norton, LJ Smith, ... ERJ open research 7 (1), 2021 | 177 | 2021 |
| Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis AI Rutherford, S Subesinghe, KL Hyrich, JB Galloway Annals of the rheumatic diseases 77 (6), 905-910, 2018 | 172 | 2018 |
| BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs J Ledingham, N Gullick, K Irving, R Gorodkin, M Aris, J Burke, P Gordon, ... Rheumatology 56 (6), 865-868, 2017 | 165 | 2017 |
| The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study SK Mahil, K Bechman, A Raharja, C Domingo-Vila, D Baudry, MA Brown, ... The Lancet Rheumatology 3 (9), e627-e637, 2021 | 164 | 2021 |
| The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for … LK Mercer, AC Green, JB Galloway, R Davies, M Lunt, WG Dixon, ... Annals of the rheumatic diseases 71 (6), 869-874, 2012 | 149 | 2012 |
| Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population LK Mercer, R Davies, JB Galloway, A Low, M Lunt, WG Dixon, KD Watson, ... Rheumatology 52 (1), 91-98, 2013 | 143 | 2013 |
| Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer … S Toback, E Galiza, C Cosgrove, J Galloway, AL Goodman, PA Swift, ... The Lancet Respiratory Medicine 10 (2), 167-179, 2022 | 132 | 2022 |
Sam NortonReader, Health Psychology & Centre for Rheumatic Diseases, KCLAdresse e-mail validée de kcl.ac.uk
